Soleus Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Soleus Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.1M	Sell	267,000 -25,000	-9%	-$1.39M	0.56%	46
2026 Q1	$17M	Buy	+292,000	New	+$13.5M	0.69%	39
2025 Q3	–	Sell	-78,800	Closed	-$2.47M	–	112
2025 Q2	$2.47M	Buy	+78,800	New	+$2.57M	0.16%	73
2024 Q1	–	Sell	-58,000	Closed	-$2.67M	–	101
2023 Q4	$2.67M	Buy	58,000 +6,000	+12%	+$212K	0.3%	51
2023 Q3	$1.78M	Sell	52,000 -14,000	-21%	-$524K	0.16%	70
2023 Q2	$2.54M	Buy	+66,000	New	+$2.62M	0.28%	65
2023 Q1	–	Sell	-38,000	Closed	-$1.5M	–	99
2022 Q4	$1.5M	Sell	38,000 -58,800	-61%	-$2.14M	0.22%	63
2022 Q3	$3.49M	Buy	96,800 +21,800	+29%	+$784K	0.47%	48
2022 Q2	$2.28M	Sell	75,000 -114,797	-60%	-$3.47M	0.36%	57
2022 Q1	$5.8M	Sell	189,797 -189,200	-50%	-$5.66M	0.75%	39
2021 Q4	$11.8M	Buy	378,997 +163,300	+76%	+$4.88M	1.19%	27
2021 Q3	$3.3M	Sell	215,697 -18,000	-8%	-$313K	0.51%	46
2021 Q2	$4.35M	Sell	233,697 -474,420	-67%	-$8.74M	0.67%	31
2021 Q1	$12.7M	Buy	708,117 +150,000	+27%	+$2.54M	2.28%	9
2020 Q4	$8.58M	Buy	558,117 +57,853	+12%	+$677K	1.13%	10
2020 Q3	$5.54M	Buy	500,264 +249,367	+99%	+$2.93M	2.94%	14
2020 Q2	$3.15M	Buy	250,897 +237,669	+1,797%	+$3.02M	1.79%	21
2020 Q1	$150K	Sell	13,228 -148,372	-92%	-$2.11M	0.17%	47
2019 Q4	$2.12M	Buy	+161,600	New	+$1.7M	2.04%	19

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Soleus Capital Management's XENE Position: Q2 2026 in Review

Soleus Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 8.6% in Q2 2026, selling an estimated $1.39M and leaving 267,000 shares worth $16.1M. The position accounts for 0.56% of the portfolio, ranked #46.

Soleus Capital Management first reported a position in XENE in Q4 2019 and has held it in 19 quarters since. The position peaked at $17M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Soleus Capital Management held 267,000 shares of Xenon Pharmaceuticals worth $16.1M as of Q2 2026.
Soleus Capital Management sold 25,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
Xenon Pharmaceuticals made up 0.56% of Soleus Capital Management's portfolio in Q2 2026, its #46 holding.
Soleus Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 19 quarters since.
Soleus Capital Management's Xenon Pharmaceuticals position peaked at $17M in Q1 2026.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.